Filing Flows › Mobia Medical (MOBI) › Guidance & outlook
Mobia Medical (MOBI) guidance and outlook
Mobia Medical (MOBI) raised its guidance on Nov 5, 2026: Revenue $57.0M–$57.5M for FY2026; Revenue +78% to +79% for FY2026. Mobia Medical's 10-Q filed Nov 5, 2026 makes 35 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $57.0M–$57.5M | raised |
| Revenue | FY2026 | +78% to +79% | raised |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- This equates to approximately 9 million ischemic stroke survivors in the United States, of which we estimate that more than 4 million are chronic ischemic stroke survivors living with moderate to severe upper extremity impairment.
- Based on a report published by the AHA in 2025, we estimate that each year approximately 200,000 new stroke survivors in the United States meet our indication for use, with 50,000 of these survivors representative of our initial market opportunity.
- Over time, we believe these centers will naturally integrate Vivistim Therapy into standard care pathways for stroke survivors upon discharge and establish self-sustaining care programs that use Vivistim Therapy.
- To accomplish this, we intend to continue to educate healthcare providers on the capabilities and benefits of Vivistim Therapy, work closely with hospitals to incorporate Vivistim Therapy as a treatment option, and activate care programs that use Vivistim Therapy at stroke centers and therapy sites.
- In addition, we intend to continue to expand our clinical evidence to support a robust cadence of publications regarding the benefits of Vivistim Therapy.
- We believe these efforts will support the growth of our business by generating broader awareness, which can support adoption and increase utilization of Vivistim Therapy.
- In addition, we engage in direct patient education activities, such as webinars, outreach through support groups, digital advertising and other targeted activities.
- For example, we believe that as awareness and utilization increase, stroke centers will naturally integrate Vivistim Therapy into standard care pathways for stroke survivors upon discharge and establish self-sustaining care programs that use Vivistim Therapy over time.
- Our financial performance will be significantly impacted by the extent to which we can increase awareness and utilization, as well as the timing and rate of adoption of our products by healthcare providers.
- To promote awareness and utilization, we expect to continue to efficiently invest in and grow our commercial organization.
- We intend to continue to make significant investments in our commercial organization by scaling our team, which we believe will broaden our geographic reach, drive penetration, and increase access to our products.
- We seek to scale deliberately and efficiently using our scalable commercial model, which initially targets a highly concentrated group of high-volume primary
Mobia Medical's latest quarter
Mobia Medical, Q3 2026: revenue $15.6M (+73% year over year), operating margin -118.7%, net loss $17.3M, operating cash flow −$12.9M. The chart follows the revenue to costs, profit and cash.
Questions
Did Mobia Medical raise or lower its guidance?
Mobia Medical (MOBI) raised its guidance on Nov 5, 2026: Revenue $57.0M–$57.5M for FY2026; Revenue +78% to +79% for FY2026.
What does Mobia Medical expect?
This equates to approximately 9 million ischemic stroke survivors in the United States, of which we estimate that more than 4 million are chronic ischemic stroke survivors living with moderate to severe upper extremity impairment. Based on a report published by the AHA in 2025, we estimate that each year approximately 200,000 new stroke survivors in the United States meet our indication for use, with 50,000 of these survivors representative of our initial market opportunity. Over time, we believe these centers will naturally integrate Vivistim Therapy into standard care pathways for stroke sur
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.